Telavancin

Telavancin is a bactericidal lipoglycopeptide under trial for use in MRSA or other Gram-positive infections.

On October 19, 2007, the US Food and Drug Administration issued an approvable letter for telavancin. Its developer, Theravance, Inc. submitted a complete response to the letter, and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of July 21, 2008.